VNRX READ THE FULL VNRX RESEARCH REPORT RECENT EVENTS Nu.Q Discover to be Utilized in a Human Clinical Study On March 4, 2025 ...

OPGx-MERTK is a gene therapy being developed by Opus Genetics to treat patients impacted by MERTK-related retinitis pigmentosa (RP). Results from a pre-clinical study which evaluated OPGx-MERTK in a ...

ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 ...

Operator Good morning, and welcome to Ocugen's fourth quarter and full-year 2024 financial results and business update.

Enrollment exceeding expectations in DURAVYU™ Phase 3 wet AMD clinical trials with LUGANO over 50% enrolled and LUCIA recruiting ahead of ...

The "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering.A recent comprehensive analysis of the Chronic ...

Women who suffer greater menopause symptoms are more likely to experience memory and thinking problems as they age, research ...

Bayer initiates phase II panSOHO study with BAY 2927088 in metastatic or unresectable HER2 mutant solid tumours: Berlin Wednesday, March 5, 2025, 09:00 Hrs [IST] Bayer announced t ...

Researchers associated with the New York-based Memorial Sloan Kettering Cancer Center have obtained positive results in the ...

Updated ASCO guidelines for pleural mesothelioma refine surgery use, recommend immunotherapy, genetic testing, and improve ...

Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease potentially expediting clinical development by two to three yearsCompleted dosing in ...

Discover 7 biotech companies in Taiwan, a rising regional player in precision medicine, immunotherapy, and drug development!